logo

For the Inventor, By the Inventor

Oita, Japan

Minoru Moriwaki

This inventor holds 12 USPTO granted patents, plus 1 CIPO patent. Top assignees: Yoshitomi Pharmaceutical Industries, Ltd., Japan Tobacco Inc.. Active years: 1983-1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Minoru Moriwaki. Retrieved from https://idiyas.com/inventor/minoru-moriwaki-qm6j0s71

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 12

% Patents Active = 100.0


Average Co-Inventor Count = 4.7

ph-index = 6

Forward Citations = 256(Granted Patents)


Location History:

  • Nakatsu, JP (1990 - 1991)
  • Oita, JP (1989 - 1994)
  • Fukuoka, JP (1983 - 1997)
  • Chikujo-gun, JP (1997 - 1998)
  • Osaka, JP (1998)

Company Filing History:

goldMedal12 out of 198 
 
Yoshitomi Pharmaceutical Industries, Ltd.
 patents
silverMedal2 out of 1,068 
 
Japan Tobacco Inc.
 patents
where one patent can have more than one assignee

Years Active: 1983-1998

Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents
1. 5760032 - Thienylazole compound and thienotriazolodiazepine compound (1998-06-02),
2. 5753649 - Therapeutic agent for osteoporosis and diazepine compound (1998-05-19),
3. 5721231 - Thienotriazolodiazepine compound and pharmaceutical use thereof (1998-02-24),
4. 5686479 - Immunosuppressive drug (1997-11-11),
5. 5593988 - Therapeutic agent for osteoporosis and diazepine compound (1997-01-14),
6. 5286858 - Optically active thienotriazolodiazepine compounds (1994-02-15),
7. 5028603 - Ester-substituted thienotriazolodiazepine compounds and pharmaceutical (1991-07-02),
8. 4960770 - 2-alkyl thieno(triazolo)diazepine compounds and pharmaceutical uses (1990-10-02),
9. 4937240 - Thienotriazolodiazepine compounds and pharmaceutical uses thereof (1990-06-26),
10. 4910194 - Thienotriazolodiazepine compounds and pharmaceutical uses thereof (1990-03-20),
11. 4820703 - PAF-antagonistic thienotriazolodiazepine compounds and pharmaceutical (1989-04-11),
12. 4386092 - Heterocyclic-substituted oxoalkanoic acid derivatives (1983-05-31),

Title: Minoru Moriwaki: Innovator in Osteoporosis Therapeutics

Introduction

Minoru Moriwaki is a distinguished inventor based in Oita, Japan, known for his significant contributions to the field of pharmaceuticals. He holds a total of 12 patents, primarily focusing on therapeutic agents for osteoporosis. His innovative work has the potential to greatly impact the treatment of bone-related diseases.

Latest Patents

Moriwaki's latest patents include the Thienylazole compound and thienotriazolodiazepine compound, which serve as therapeutic agents for osteoporosis. These compounds are designed to inhibit bone resorption and reduce elevated calcium levels in the blood serum, which are often associated with conditions like Paget's disease and hypercalcemia. The compounds demonstrate superior bone resorption-inhibitory activity, making them valuable in preventing the decrease of bone mass and managing symptoms related to inflammatory joint diseases such as rheumatoid arthritis.

Career Highlights

Throughout his career, Moriwaki has worked with notable companies, including Yoshitomi Pharmaceutical Industries, Ltd. and Japan Tobacco Inc. His experience in these organizations has contributed to his expertise in pharmaceutical development and innovation.

Collaborations

Moriwaki has collaborated with esteemed colleagues, including Tetsuya Tahara and Michio Terasawa, further enhancing his research and development efforts in the pharmaceutical industry.

Conclusion

Minoru Moriwaki's work in developing therapeutic agents for osteoporosis showcases his dedication to advancing medical science. His innovative compounds hold promise for improving the quality of life for individuals affected by bone-related diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…